Option Care Health, Inc. — Q1 2023 Form 10-Q
Business and period: National provider of infusion therapy and related healthcare services, operating 95 full-service pharmacies and 73 ambulatory infusion suites. Results cover the three months ended March 31, 2023, compared with Q1 2022. Unless noted, amounts are U.S. dollars.
Financial performance and position
- Revenue: $1.016 billion, up 10.9% from $915.8 million. Commercial payer revenue was $873.9 million; government payer revenue was $122.8 million; patient revenue was $19.1 million.
- Profit and margins: Gross profit was $229.0 million, up 14.0%; gross margin was 22.5%, versus 21.9%. Operating income was $66.6 million, versus $52.2 million; operating margin was 6.6%, versus 5.7%. Net income was $39.2 million, up 29.5%, with a 3.9% net margin versus 3.3%. Diluted EPS was $0.21, versus $0.17.
- Expenses and interest: SG&A rose 10.4% to $147.9 million but remained 14.6% of revenue. Net interest expense increased 13.0% to $13.8 million, principally due to higher variable interest rates.
- Cash flow: Operating cash flow was $89.8 million, versus $32.7 million. Capital expenditures were $5.8 million; investing cash outflow was $5.8 million. Financing cash outflow was $80.4 million, including a $75.0 million share repurchase. Cash increased $3.6 million to $297.8 million.
- Liquidity and debt: Cash was $297.8 million, and net borrowing availability under the ABL facility was $219.5 million. Debt principal totaled $1.093 billion (carrying value, net of discounts and costs, was $1.064 billion); the First Lien Term Loan carried a 7.38% rate at quarter-end and Senior Notes carried 4.375%. The company stated existing cash and expected operating cash flows should cover operating needs over the next 12 months and beyond.
Changes, outlook and notable items
- Management attributed revenue growth mainly to organic growth: acute therapies grew at a mid-single-digit rate and chronic therapies at a low-double-digit rate. Acquisition-related growth contributed about 1% of the increase in revenue and gross profit. Growth was partly offset by divestitures of respiratory therapy assets and therapies for ALS and pre-term labor.
- Gross profit growth outpaced revenue growth, which management attributed primarily to procurement discipline and efficient infusion-suite utilization, partly offset by inflation. SG&A growth reflected acquired employees and inflation, offset by spending controls.
- No specific financial guidance was provided in the supplied filing text. Management cited continued investment in pharmacy and IT infrastructure and acquisitions as strategic priorities; future acquisitions may require additional capital.
- On May 3, 2023, after quarter-end, the company agreed to merge with Amedisys. Option Care Health stockholders are expected to own approximately 64.5% of the combined company. Closing was expected in the second half of 2023, subject to stockholder and regulatory approvals and other conditions. A debt commitment provides for up to $450 million of secured bridge financing to refinance Amedisys debt and pay related costs.
- The company repurchased 2,475,166 shares from HC I for $75.0 million at an average price of $30.30. The $250 million repurchase authorization had $175 million remaining at March 31.
- Key exposures include reimbursement estimation and government-program rules, dependence on a concentrated supplier base (four vendors represented approximately 72% of pharmaceutical and medical supply purchases), variable-rate debt, and legal and regulatory proceedings. Management said pending matters were not expected to materially affect the balance sheet, while acknowledging adverse outcomes could affect results or cash flows. It reported no material changes to previously disclosed risk factors and effective disclosure controls.
Important facts for investors to verify
- Whether organic growth, especially chronic therapy growth, continues and whether procurement and utilization gains sustain gross-margin improvement.
- Cash-flow quality and working-capital movements, including the effect of vendor-payment timing and inventory levels.
- Exposure to higher variable interest rates, effectiveness of the interest-rate cap, and debt repayment requirements.
- Merger closing conditions, regulatory and stockholder approvals, financing terms, and the ultimate impact of the Amedisys transaction.
- Share-repurchase pace and its effect on cash, liquidity, and outstanding shares, alongside capital needs for acquisitions and infrastructure.